↓ Skip to main content

Idiopathic Intracranial Hypertension (Pseudotumor Cerebri): Recognition, Treatment, and Ongoing Management

Overview of attention for article published in Current Treatment Options in Neurology, November 2012
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
106 Dimensions

Readers on

mendeley
259 Mendeley
Title
Idiopathic Intracranial Hypertension (Pseudotumor Cerebri): Recognition, Treatment, and Ongoing Management
Published in
Current Treatment Options in Neurology, November 2012
DOI 10.1007/s11940-012-0207-4
Pubmed ID
Authors

Matthew J. Thurtell, Michael Wall

Abstract

Idiopathic intracranial hypertension (IIH, pseudotumor cerebri) is a syndrome of elevated intracranial pressure of unknown cause that occurs predominantly in obese women of childbearing age. It is a diagnosis of exclusion and, therefore, other causes of increased intracranial pressure must be sought with history, imaging, and cerebrospinal fluid examination before the diagnosis can be made. IIH produces symptoms and signs of increased intracranial pressure, including papilledema. If untreated, papilledema can cause progressive irreversible visual loss and optic atrophy. The treatment approach depends on the severity and time course of symptoms and visual loss, as determined by formal visual field testing. The main goals of treatment are alleviation of symptoms, including headache, and preservation of vision. All overweight IIH patients should be encouraged to enter a weight-management program with a goal of 5-10 % weight loss, along with a low-salt diet. When there is mild visual loss, medical treatment with acetazolamide should be initiated. Other medical treatments can be added or substituted when acetazolamide is insufficient as monotherapy or poorly tolerated. When visual loss is more severe or rapidly progressive, surgical interventions, such as optic nerve sheath fenestration or cerebrospinal fluid shunting, may be required to prevent further irreversible visual loss. The choice of intervention depends on the relative severity of symptoms and visual loss, as well as local expertise. At present, the role of transverse venous sinus stenting remains unclear. Although there are no evidence-based data to guide therapy, there is an ongoing randomized double-blind placebo-controlled treatment trial, investigating diet and acetazolamide therapy for IIH.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 259 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 2 <1%
South Africa 1 <1%
Canada 1 <1%
Australia 1 <1%
Unknown 254 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 36 14%
Unspecified 29 11%
Student > Ph. D. Student 23 9%
Student > Master 23 9%
Student > Doctoral Student 22 8%
Other 73 28%
Unknown 53 20%
Readers by discipline Count As %
Medicine and Dentistry 100 39%
Unspecified 29 11%
Neuroscience 16 6%
Nursing and Health Professions 10 4%
Agricultural and Biological Sciences 7 3%
Other 33 13%
Unknown 64 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 June 2017.
All research outputs
#15,256,044
of 22,685,926 outputs
Outputs from Current Treatment Options in Neurology
#300
of 468 outputs
Outputs of similar age
#115,473
of 183,504 outputs
Outputs of similar age from Current Treatment Options in Neurology
#8
of 10 outputs
Altmetric has tracked 22,685,926 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 468 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one is in the 26th percentile – i.e., 26% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 183,504 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.